Hims & Hers Health
HIMS
Performance
About Hims & Hers Health
Hims is a 100% online telehealth platform focused on men’s wellness, offering clinician-guided assessments and prescription treatments for conditions such as hair loss, erectile dysfunction, weight management, and skin care. The company operates across the United States, providing doctor consultations, medication shipped to customers, and at-home lab testing to personalize treatment plans. With a broad product portfolio and a patient-centric approach, Hims emphasizes discreet, accessible care through an all-online process and a mobile app. Headquartered in San Francisco, it serves millions of subscribers with licensed providers and FDA-regulated pharmacies.
Recent News
Hims Breach Exposes the Most Sensitive Kinds of PHI
Hims & Hers Expands Personalized Digital Healthcare Platform
Pre-Markets Down on Oil Prices, Q1 Earnings Results
Former Apple Exec Leaves Ford in Tech Reorganization
Market Crosscurrents: Bulls in Control, Macro Headwinds Loom
Here’s How Much Weight-Loss Drugs Wegovy, Zepbound and Foundayo Cost — and How to Pick the Best GLP-1 for You
10 Stocks With Unexpected Gains
Ceasefire Extension, Best Buy's New CEO, Amazon's GLP-1 Push and More in Morning Squawk
Hims & Hers Health, Inc. Dba Hers - 716825 - 09/09/2025
🎯 Covered Call Trade Management Alert For $HIMS
How AI Helped 1 Man (and His Brother) Build a $1.8 Billion Company
Hims & Hers Launches Integrated AI‑Driven Digital Health Platform
Stocks Recover as Oil Retreats From $119: Stock Market Today
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus
Pre-Market IV Report April 20, 2026
Stock Market Week: Nvidia Earnings, Apple And Strategy Events
Hims & Hers Shares Slide 8% After $300M Convertible Notes Offering
Can DUK's Grid Modernization Drive Long-Term Growth and Reliability?
Dow Hits Record as Retail Sales Stall | Closing Bell
Stock Market Today: Indexes Pull Back After Core CPI Hotter Than Expected; Oil Prices Rise on Tenuous US-Iran Ceasefire
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
Nasdaq, S&P 500 Enjoy Another Record-Breaking Week
Pen and Tell Her (2 of 4)
Hims & Hers Acquires Australian Digital Health Eucalyptus for Up to $1.15B
Market Update: TPR, EQR, CBOE
Stock Market Today: Dow Drops, Nasdaq Falls On $100 Oil, South Korea AI News; Inflation Pops (Live Coverage)
Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations
Hims & Hers Gains 7% on FDA Peptide Review, Faces Amazon Competition
Novo, Lilly Sputter as Hims Launches Knockoff GLP-1 Pill